Roivios Ltd., a clinical-stage medical device developer focused on kidney health, has reported promising results from its first-in-human trial of the JuxtaFlow Renal Assist Device. This investigational system applies controlled negative pressure to the renal pelvis to enhance urine output and sodium excretion in patients with diuretic-resistant cardiorenal syndrome and acute decompensated heart failure. While the trial included only seven patients, the published results suggest meaningful physiologic improvement over standard care.

The study follows an earlier milestone for Roivios, when the United States Food and Drug Administration granted Investigational Device Exemption approval for the GRADIENT trial, a separate pivotal study targeting kidney support during cardiac surgery. The company is now pursuing a two-pronged strategy, positioning JuxtaFlow as a potential disruptor in both heart failure and perioperative renal care.

Why the current model for fluid management in heart failure is breaking down

Cardiorenal syndrome remains one of the most complex challenges in hospitalized heart failure care. Despite the central role of loop diuretics in managing fluid overload, many patients eventually become resistant, leading to worsening renal function, longer hospitalizations, and higher mortality. Approximately 20 percent of patients admitted with acute decompensated heart failure experience some form of diuretic resistance, often creating a clinical cascade that limits therapeutic options.

In these cases, clinicians may turn to ultrafiltration or other extracorporeal renal support modalities, but outcomes have been mixed. Devices such as the Aquadex FlexFlow system have shown promise in fluid removal but have failed to consistently improve long-term outcomes in large trials. Moreover, they add operational complexity and require continuous monitoring in high-resource settings.

JuxtaFlow proposes a fundamentally different model. Rather than extracting fluid externally, it aims to restore the kidney’s native filtration capacity by relieving venous congestion at the organ’s outflow point. This localized negative pressure, applied via a catheter-based pump system, is designed to enhance glomerular filtration while preserving blood pressure and renal perfusion.

What the VOID-HF trial reveals about JuxtaFlow’s physiological effect

The Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF) feasibility trial enrolled seven patients across three United States medical centers. All participants were hospitalized with acute decompensated heart failure and demonstrated signs of diuretic resistance.

Results published in the ASAIO Journal show a statistically significant increase in 24-hour urine output from 2.27 liters to 3.85 liters during device use. Sodium excretion nearly doubled, rising from 78 to 145 millimoles. Importantly, these changes occurred without the need for escalating diuretic dosing, indicating JuxtaFlow’s potential to enhance natriuresis independently.

No structural kidney damage was detected on post-treatment imaging. Safety signals were limited to one transient case of hematuria and one reversible episode of reflux anuria. According to clinicians familiar with the data, the safety profile, though early, is consistent with a non-destructive mode of action and supports expansion into larger trials.

While the study lacks a control group, the magnitude of change and tolerability are being viewed as a legitimate signal of device feasibility in an otherwise hard-to-treat population.

How JuxtaFlow’s approach differs from ultrafiltration and peritoneal dialysis

Unlike ultrafiltration devices, which pull fluid from the blood through an extracorporeal circuit, JuxtaFlow manipulates the local hydrostatic environment within the kidney itself. The system operates by inserting a proprietary catheter into the renal pelvis and applying continuous low-level suction. This reduces the backpressure on glomerular capillaries, theoretically enhancing filtration and enabling greater fluid and sodium clearance.

This mechanism contrasts with dialysis methods that require systemic filtration and electrolyte balancing. The localized nature of JuxtaFlow’s therapy may lower the threshold for use and reduce the need for dedicated dialysis staff or infrastructure.

Additionally, peritoneal dialysis, while effective in select outpatient populations, is not widely adopted in acute heart failure due to logistical barriers. JuxtaFlow may offer a more adaptable option that fits into existing heart failure treatment pathways, especially in hospitals lacking renal replacement capabilities.

However, integration will depend on ease of catheter placement, nursing protocols, and consistency of outcomes in broader patient groups. Clinical workflow adaptation will remain a central question in subsequent studies.

Why FDA breakthrough designation and IDE approval are critical to Roivios’ trajectory

In April 2024, the United States Food and Drug Administration granted Breakthrough Device Designation to the JuxtaFlow Renal Assist Device, citing its potential to address a life-threatening condition with no current alternatives. This designation enabled enhanced communication with regulators and set the stage for expedited review.

By December 2024, Roivios had secured IDE approval for the GRADIENT trial, which is now underway. GRADIENT will assess JuxtaFlow in patients undergoing cardiopulmonary bypass with pre-existing renal insufficiency—a cohort at high risk for postoperative acute kidney injury.

This trial is being led by Dr. Evelio Rodriguez of Ascension Saint Thomas in Nashville, Tennessee. It is structured as a prospective, multicenter, randomized study, with the goal of evaluating JuxtaFlow’s ability to preserve renal function during and after cardiac surgery.

For Roivios, success in GRADIENT could validate a second major indication beyond heart failure. It would also significantly expand the device’s addressable market, positioning JuxtaFlow not only as a rescue tool but as a prophylactic measure in high-risk surgery.

What barriers still stand between JuxtaFlow and widespread clinical adoption

While enthusiasm around the concept of renal negative pressure therapy is growing, several real-world constraints remain. Most notably, the VOID-HF data set is limited to a small number of patients, and the absence of a control arm limits definitive conclusions. Larger randomized trials will need to confirm whether the physiological improvements seen translate into fewer readmissions, reduced dialysis, or survival benefits.

There are also operational concerns. Catheter placement requires specific expertise and may not be suitable for all patients. It remains unclear how well the system performs across different care settings, including community hospitals or outpatient infusion centers.

Cost will be another consideration. Although JuxtaFlow may reduce length of stay or prevent progression to dialysis, initial capital costs and disposable components will need to be justified through health economic analyses.

Additionally, the device’s proprietary design may pose challenges for scaling production if demand surges, particularly if both the heart failure and surgical markets open simultaneously.

Where JuxtaFlow fits within the evolving renal device landscape

JuxtaFlow is part of a growing wave of device-based interventions targeting kidney function during critical illness. Companies such as Outset Medical, Qidni Labs, and AWAK Technologies are also exploring alternatives to traditional dialysis, including portable and wearable platforms.

However, JuxtaFlow’s approach is uniquely focused on enhancing native kidney function through mechanical modulation rather than filtration or exchange. Its success could pave the way for new classes of “renal assist” devices aimed at maintaining homeostasis rather than replacing renal function entirely.

Analysts suggest that Roivios could become an acquisition target if the GRADIENT trial succeeds, particularly for larger players with cardiovascular or critical care portfolios. Potential suitors could include companies with a presence in heart failure, surgical perfusion, or catheter-based renal therapies.

Whether Roivios scales independently or via partnership, the data emerging from its early studies suggests that kidney support in fluid-overloaded and perioperative patients may soon have more options than diuretics or dialysis alone.

What clinicians and regulators will be watching next

The next 12 to 18 months will be crucial for JuxtaFlow’s trajectory. Clinicians are looking for evidence that the device offers reproducible benefits in broader patient populations and across different hospital workflows. Regulators will be focused on safety endpoints, particularly in the GRADIENT trial where device placement occurs intraoperatively.

Reimbursement agencies and hospital systems will want to see whether use of the device correlates with tangible cost savings through shorter ICU stays, fewer complications, or reduced dialysis referrals.

Ultimately, JuxtaFlow’s promise lies not just in its novel mechanism, but in its ability to bridge the gap between traditional medical therapy and invasive renal support. If successful, Roivios could help redefine how kidney function is managed in some of the most vulnerable patients in the healthcare system.

  cardiorenal syndrome, critical care nephrology, diuretic resistance, heart failure, JuxtaFlow Renal Assist Device, medical device innovation, negative pressure therapy, renal support devices, Roivios